Summary Points
- Nine tumors have been reported among Zolgensma-treated patients since its 2019 approval.
- Two cases showed vector integration; seven others remain unlinked, with causality not established.
- Novartis says over 6,000 patients received treatment and continues monitoring reported safety information.
- SMA Europe urged timely public updates as regulators assess evidence and potential next steps.
Nine tumor reports prompt fresh questions
Novartis says nine tumors have been reported in patients treated with Zolgensma, its gene therapy for spinal muscular atrophy (SMA). However, the reports do not establish that the treatment caused all nine tumors.
In two cases, tests found evidence that the therapy’s viral vector had integrated into patients’ DNA. The company says both patients received treatment and remain under monitoring. The other seven reports have not been causally linked to Zolgensma.
A breakthrough with risks to monitor
Approved in 2019 for children younger than 2, Zolgensma delivers a working copy of a gene involved in producing a protein needed by motor neurons. SMA can severely weaken muscles and affect a child’s ability to move, breathe and swallow. For families, a one-time treatment can offer meaningful hope.
Still, gene therapies require long-term safety checks. Zolgensma’s prescribing information already warns of a potential tumor risk related to its viral vector. More than 6,000 patients have received the therapy in trials, access programs or commercial treatment, Novartis says.
Clear updates matter to families
Patient advocates are seeking timely public communication, while regulators assess the available evidence. That process matters in daily life: Families need clear information to discuss follow-up care with their doctors, without mistaking a reported event for a proven cause.
The reports also show why scientific progress and careful monitoring must move together. Zolgensma has offered a treatment option for a serious disease. Continued evaluation can help patients and clinicians weigh its benefits and risks with greater confidence.
Continue Your Tech Journey
Learn how the Internet of Things (IoT) is transforming everyday life.
Learn more about cutting-edge innovations supported by the National Science Foundation (NSF).
Sci-BioV1
